Cabio Biotech (Wuhan) Co., Ltd.

SHSE:688089 Voorraadrapport

Marktkapitalisatie: CN¥3.5b

Cabio Biotech (Wuhan) Beheer

Beheer criteriumcontroles 3/4

De CEO Cabio Biotech (Wuhan) is Dewei Yi, benoemd in Dec2015, heeft een ambtstermijn van 8.92 jaar. bezit rechtstreeks 1.39% van de aandelen van het bedrijf, ter waarde CN¥ 48.77M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.9 jaar en 5.9 jaar.

Belangrijke informatie

Dewei Yi

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO8.9yrs
Eigendom CEO1.4%
Management gemiddelde ambtstermijn8.9yrs
Gemiddelde ambtstermijn bestuur5.9yrs

Recente managementupdates

Recent updates

Cabio Biotech (Wuhan) (SHSE:688089) Might Be Having Difficulty Using Its Capital Effectively

Oct 28
Cabio Biotech (Wuhan) (SHSE:688089) Might Be Having Difficulty Using Its Capital Effectively

Subdued Growth No Barrier To Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) With Shares Advancing 31%

Oct 01
Subdued Growth No Barrier To Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) With Shares Advancing 31%

There's Reason For Concern Over Cabio Biotech (Wuhan) Co., Ltd.'s (SHSE:688089) Massive 25% Price Jump

Aug 06
There's Reason For Concern Over Cabio Biotech (Wuhan) Co., Ltd.'s (SHSE:688089) Massive 25% Price Jump

Cabio Biotech (Wuhan) (SHSE:688089) Could Be Struggling To Allocate Capital

Jun 07
Cabio Biotech (Wuhan) (SHSE:688089) Could Be Struggling To Allocate Capital

Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

May 06
Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

Cabio Biotech (Wuhan)'s (SHSE:688089) Promising Earnings May Rest On Soft Foundations

May 03
Cabio Biotech (Wuhan)'s (SHSE:688089) Promising Earnings May Rest On Soft Foundations

The Market Lifts Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Shares 27% But It Can Do More

Mar 21
The Market Lifts Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Shares 27% But It Can Do More

CEO

Dewei Yi (59 yo)

8.9yrs

Tenure

CN¥1,179,900

Compensatie

Mr. Dewei Yi is Chairman of the Board & General Manager of CABIO Biotech(Wuhan) Co., Ltd., since December 2015. From December 1999 he has been the chairman of Wuhan Xiwang Biological Engineering Co., Ltd.;...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Dewei Yi
Chairman of the Board & GM8.9yrsCN¥1.18m1.39%
CN¥ 48.8m
Huabiao Wang
CFO & Director8.9yrsCN¥999.30k0.66%
CN¥ 23.2m
Huarong Yi
Board Secretary & Deputy GM2.9yrsCN¥620.30k0.089%
CN¥ 3.1m
Zhiming Wang
Deputy General Manager2.9yrsCN¥794.60k0.14%
CN¥ 5.0m
Min Xiao
Chief Engineer & Application Technology Director8.9yrsgeen gegevens0.042%
CN¥ 1.5m

8.9yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 688089 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.9 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Dewei Yi
Chairman of the Board & GM8.9yrsCN¥1.18m1.39%
CN¥ 48.8m
Huabiao Wang
CFO & Director8.9yrsCN¥999.30k0.66%
CN¥ 23.2m
Bin Du
Vice Chairman of the Board8.9yrsCN¥990.70k0.58%
CN¥ 20.4m
Junyu Wu
Employee Supervisor8.9yrsgeen gegevens0.018%
CN¥ 639.8k
Chunyu Zhang
Director2.9yrsgeen gegevensgeen gegevens
Xiangdong Chen
Independent Director2.9yrsCN¥80.00kgeen gegevens
Qi Liu
Independent Director2.9yrsCN¥80.00kgeen gegevens
Jing Chen
Supervisor2.9yrsgeen gegevensgeen gegevens

5.9yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 688089 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.9 jaar).